{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T01:17:48Z","timestamp":1776820668627,"version":"3.51.2"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.diabres.2020.108556","type":"journal-article","created":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T22:19:58Z","timestamp":1606169998000},"page":"108556","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Patterns and preferences of antidiabetic drug use in Turkish patients with type 2 diabetes \u2013 A nationwide cross-sectional study (TEMD treatment study)"],"prefix":"10.1016","volume":"171","author":[{"given":"Cem","family":"Haymana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alper","family":"Sonmez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Demirci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guzin","family":"Fidan Yaylal\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irfan","family":"Nuhoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seda","family":"Sancak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murat","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuksel","family":"Altuntas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nevin","family":"Dinccag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tevfik","family":"Sabuncu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fahri","family":"Bayram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilhan","family":"Satman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2020.108556_b0005","unstructured":"International Diabetes Federation. IDF Diabetes Atlas, 8th edn. Brussels, Belgium:International Diabetes Federation, 2017. 2017. ISBN: 978-2-930229-87-4"},{"issue":"1","key":"10.1016\/j.diabres.2020.108556_b0010","doi-asserted-by":"crossref","first-page":"e000297","DOI":"10.1136\/bmjdrc-2016-000297","article-title":"Resource use associated with type 2 diabetes in Africa, the Middle East, South Asia, Eurasia and Turkey: results from the International Diabetes Management Practice Study (IDMPS)","volume":"5","author":"Gagliardino","year":"2017","journal-title":"BMJ Open Diab Res Care"},{"key":"10.1016\/j.diabres.2020.108556_b0015","unstructured":"SEMT Diabetes Mellitus Study Group. Clinical Practice Guideline for Diagnosis, Treatment, and Follow-up of Diabetes Mellitus and Its Complications-2019. 12th Edition, 2019. ISBN: 978-605-4011-38-4."},{"key":"10.1016\/j.diabres.2020.108556_b0020","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2019. 2019;42(Suppl 1):S90-S102. doi:10.2337\/dc19-S009.","DOI":"10.2337\/dc19-S009"},{"issue":"11","key":"10.1016\/j.diabres.2020.108556_b0025","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/j.clinthera.2017.09.016","article-title":"Factors associated with type 2 diabetes mellitus treatment choice across four european countries","volume":"39","author":"Heintjes","year":"2017","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.diabres.2020.108556_b0030","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2458-13-602","article-title":"Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables","volume":"13","author":"Ji","year":"2013","journal-title":"BMC Public Health"},{"issue":"1","key":"10.1016\/j.diabres.2020.108556_b0035","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2337\/dc17-1414","article-title":"Long-term trends in antidiabetes drug usage in the U.S.: Real-world evidence in patients newly diagnosed with type 2 diabetes","volume":"41","author":"Montvida","year":"2018","journal-title":"Dia Care"},{"key":"10.1016\/j.diabres.2020.108556_b0040","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.diabres.2016.06.018","article-title":"The prevalence and treatment patterns of diabetes in the Greek population based on real-world data from the nation-wide prescription database","volume":"118","author":"Liatis","year":"2016","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"10.1016\/j.diabres.2020.108556_b0045","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.diabres.2014.12.007","article-title":"Trends in the prescription of antidiabetic medications from 2009 to 2012 in a general practice of Southern Italy: A population-based study","volume":"108","author":"Rafaniello","year":"2015","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"10.1016\/j.diabres.2020.108556_b0050","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4274\/tjem.3120","article-title":"The international diabetes management practices study (IDMPS) - Turkey\u2019s 5th wave results","volume":"20","author":"\u0130lkova","year":"2016","journal-title":"tjem"},{"key":"10.1016\/j.diabres.2020.108556_b0055","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1262-3636(07)70124-6","article-title":"Vascular Risk Study Group. Sub-optimal drug treatment of diabetes and cardiovascular risk in diabetic patients in Turkey. A countrywide survey","volume":"30","author":"Damci","year":"2004","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabres.2020.108556_b0060","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.diabres.2018.09.010","article-title":"Turkish nationwide survEy of glycemic and other Metabolic parameters of patients with Diabetes mellitus (TEMD study)","volume":"146","author":"Sonmez","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabres.2020.108556_b0065","unstructured":"TEMD Diabetes Mellitus \u00c7al\u0131\u015fma Grubu. Diabetes Mellitus ve Komplikasyonlar\u0131n\u0131n Tan\u0131, Tedavi ve Izlem K\u0131lavuzu-2017. 9. Bask\u0131, T\u00fcrkiye Endokrinoloji ve Metabolizma Dernegi (TEMD) Yay\u0131nlar\u0131, Bayt Matbaac\u0131l\u0131k, Ankara, 2017. ISBN: 978-605-4011-26-1"},{"key":"10.1016\/j.diabres.2020.108556_b0070","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. 9. Cardiovascular Disease and Risk Management. 2017;40(Suppl 1):S75-S87. doi:10.2337\/dc17-S012.","DOI":"10.2337\/dc17-S012"},{"key":"10.1016\/j.diabres.2020.108556_b0075","unstructured":"World Health Organization. Obesity: Preventing and managing the global epidemic. Report of a WHO consultation. WHO technical report series no. 894. 2000. ISBN: 92 4 120894 5"},{"key":"10.1016\/j.diabres.2020.108556_b0080","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"10.1016\/j.diabres.2020.108556_b0085","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/BF02849973","article-title":"Trends in the prescription of antidiabetic medications in France: evidence from primary care physicians","volume":"24","author":"Boyc","year":"2007","journal-title":"Adv Ther"},{"key":"10.1016\/j.diabres.2020.108556_b0090","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004018","article-title":"Trends of antidiabetic drug use in adult type 2 diabetes in Korea in 2002\u20132013: Nationwide population-based cohort study","volume":"95","author":"Ko","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.diabres.2020.108556_b0095","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.pcd.2019.05.009","article-title":"Trends in global prescribing of antidiabetic medicines in primary care: A systematic review of literature between 2000\u20132018","volume":"13","author":"Ramzan","year":"2019","journal-title":"Prim Care Diabetes"},{"key":"10.1016\/j.diabres.2020.108556_b0100","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1586\/17512433.2016.1159512","article-title":"Is gliclazide a sulfonylurea with difference? A review in 2016","volume":"9","author":"Singh","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.diabres.2020.108556_b0105","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2147\/DMSO.S120101","article-title":"Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015","volume":"9","author":"Higgins","year":"2016","journal-title":"Dmso"},{"key":"10.1016\/j.diabres.2020.108556_b0110","article-title":"The prescription pattern of initial treatment for type 2 diabetes in Beijing from 2011 to 2015","volume":"98","author":"Wang","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.diabres.2020.108556_b0115","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/dmrr.2827","article-title":"Standards of care for type 2 diabetes in China","volume":"32","author":"Weng","year":"2016","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.diabres.2020.108556_b0120","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/dom.13083","article-title":"Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second-line therapy after metformin monotherapy: Retrospective data for 10 256 individuals from the United Kingdom and Germany","volume":"20","author":"Khunti","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2020.108556_b0125","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2015-000093","article-title":"Clinical characteristics, complications, comorbidities and treatment patterns among patients with type 2 diabetes mellitus in a large integrated health system","volume":"3","author":"Pantalone","year":"2015","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.diabres.2020.108556_b0130","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s00592-018-01284-4","article-title":"Diabetes management and treatment approaches outside of North America and West Europe in 2006 and 2015","volume":"56","author":"Tabesh","year":"2019","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.diabres.2020.108556_b0135","doi-asserted-by":"crossref","unstructured":"Selvin E, Parrinello CM, Daya N, Bergenstal RM. Trends in Insulin Use and Diabetes Control in the U.S.: 1988-1994 and 1999-2012. Dia Care 2016;39:e33\u20135. doi:10.2337\/dc15-2229.","DOI":"10.2337\/dc15-2229"},{"key":"10.1016\/j.diabres.2020.108556_b0140","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1185\/03007995.2011.555755","article-title":"Clinical outcomes after insulin initiation in patients with type 2 diabetes: 6-month data from the INSTIGATE observational study in five European countries","volume":"27","author":"Liebl","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.diabres.2020.108556_b0145","doi-asserted-by":"crossref","first-page":"403","DOI":"10.5414\/CP202906","article-title":"Regional differences in insulin therapy regimens in five European countries","volume":"55","author":"Rathmann","year":"2017","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.diabres.2020.108556_b0150","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1177\/0897190018815048","article-title":"National trends in diabetes medication use in the United States: 2008 to 2015","volume":"33","author":"Raval","year":"2020","journal-title":"J Pharm Pract"},{"key":"10.1016\/j.diabres.2020.108556_b0155","doi-asserted-by":"crossref","DOI":"10.4158\/EP-2019-0023","article-title":"The impact of Glp-1 receptor agonists on patients with diabetes on insulin therapy","author":"Gyorffy","year":"2019","journal-title":"Endocrine Practice"},{"key":"10.1016\/j.diabres.2020.108556_b0160","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1055\/s-0042-120708","article-title":"Add on exenatide treatment is beneficial in poorly controlled obese type 2 diabetics under intensive insulin regimens","volume":"125","author":"Sonmez","year":"2017","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.diabres.2020.108556_b0165","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1001\/jama.286.10.1218","article-title":"Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials","volume":"286","author":"Boul\u00e9","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.diabres.2020.108556_b0170","doi-asserted-by":"crossref","first-page":"357","DOI":"10.7326\/0003-4819-147-6-200709180-00005","article-title":"Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes: a randomized trial","volume":"147","author":"Sigal","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.diabres.2020.108556_b0175","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jdiacomp.2008.12.008","article-title":"Factors associated with poor glycemic control among patients with type 2 diabetes","volume":"24","author":"Khattab","year":"2010","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.diabres.2020.108556_b0180","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.diabres.2008.09.006","article-title":"Use of anti-diabetic drugs and glycaemic control in type 2 diabetes\u2014The Hong Kong Diabetes Registry","volume":"82","author":"Tong","year":"2008","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabres.2020.108556_b0185","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.diabet.2009.11.006","article-title":"Time to insulin treatment and factors associated with insulin prescription in Swedish patients with type 2 diabetes","volume":"36","author":"Ringborg","year":"2010","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabres.2020.108556_b0190","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s11606-017-4282-9","article-title":"Predictors of insulin initiation in patients with type 2 diabetes: an analysis of the look AHEAD randomized trial","volume":"33","author":"Pilla","year":"2018","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.diabres.2020.108556_b0195","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.diabres.2010.09.033","article-title":"Predictors of switching to insulin from non-insulin therapy in patients with type 2 diabetes mellitus","volume":"92","author":"Janghorbani","year":"2011","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabres.2020.108556_b0200","article-title":"Prevalence of obesity and its influence on achievement of cardiometabolic therapeutic goals in chinese type 2 diabetes patients: an analysis of the nationwide, cross-sectional 3B study","volume":"11","author":"Zhou","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.diabres.2020.108556_b0205","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12933-016-0341-5","article-title":"LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial","volume":"15","author":"Masmiquel","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabres.2020.108556_b0210","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000496624","article-title":"Impact of obesity on the metabolic control of type 2 diabetes: results of the turkish nationwide survey of glycemic and other metabolic parameters of patients with diabetes mellitus (TEMD obesity study)","volume":"12","author":"Sonmez","year":"2019","journal-title":"Obes Facts"},{"key":"10.1016\/j.diabres.2020.108556_b0215","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1023\/B:EJEP.0000032351.42772.e7","article-title":"Patient characteristics do not predict poor glycaemic control in type 2 diabetes patients treated in primary care","volume":"19","author":"Goudswaard","year":"2004","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.diabres.2020.108556_b0220","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2337\/dc08-0435","article-title":"Multifaceted determinants for achieving glycemic control: the International Diabetes Management Practice Study (IDMPS)","volume":"32","author":"Chan","year":"2009","journal-title":"Dia Care"},{"key":"10.1016\/j.diabres.2020.108556_b0225","article-title":"Hba1c, blood pressure, and lipid control in people with diabetes: Japan epidemiology collaboration on occupational health study","volume":"11","author":"Hu","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.diabres.2020.108556_b0230","doi-asserted-by":"crossref","unstructured":"Quah JHM, Liu YP, Luo N, How CH, Tay EG. Younger adult type 2 diabetic patients have poorer glycaemic control: a cross-sectional study in a primary care setting in Singapore. 2013;13:18. doi:10.1186\/1472-6823-13-18.","DOI":"10.1186\/1472-6823-13-18"},{"key":"10.1016\/j.diabres.2020.108556_b0235","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1001\/jamainternmed.2014.7345","article-title":"Potential overtreatment of diabetes mellitus in older adults with tight glycemic control","volume":"175","author":"Lipska","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.diabres.2020.108556_b0240","doi-asserted-by":"crossref","first-page":"569","DOI":"10.7326\/M17-0939","article-title":"Hemoglobin A1c targets for glycemic control with pharmacologic therapy for nonpregnant adults with type 2 diabetes mellitus: a guidance statement update from the American college of physicians","volume":"168","author":"Qaseem","year":"2018","journal-title":"Ann Intern Med"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822720308135?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822720308135?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:14:37Z","timestamp":1759173277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822720308135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":48,"alternative-id":["S0168822720308135"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2020.108556","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patterns and preferences of antidiabetic drug use in Turkish patients with type 2 diabetes \u2013 A nationwide cross-sectional study (TEMD treatment study)","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2020.108556","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108556"}}